Main information



  • Available in:
  • Mediherb P2-Detox
  • Language:
  • English

Other information


  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 218993
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:


Mediherb P2-Detox

ARTG entry for

Medicine Listed


Integria Healthcare Australia Pty Ltd

Postal Address



ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.


1. Mediherb P2-Detox

Product Type

Single Medicine Product

Effective date



If symptoms persist consult your healthcare practitioner (or words to that effect).

For practitioner dispensing only.

Standard Indications

Specific Indications

Sulforaphane from Broccoli sprouts are potent inducer of phase II detoxification enzymes.

Broccoli sprouts, turmeric, and the amino acids glycine, taurine, cysteine and methionine support normal phase 2 detoxification processes in the liver.

Helps to induce phase II detoxification enzymes.

Traditionally used in Herbal Medicine as a heapatoprotectant / liver protectant .

Turmeric and its active constituent curcumin possess antioxidant activity.

Antioxidant / Has anti-oxidising effect.

The conjugation of bile acids with taurine and glycine results in the emulsification and absorption of lipids and fat-soluble vitamins in the intestinal tract.

Contains precursors for the synthesis of the antioxidant tripeptide glutathione, which plays an important role in hepatic detoxification.

Helps support normal mucosal integrity of the gut / Helps to maintain gut barrier function.

Contains glutamine, which is the principal energy source of epithelial and immune cells in the gastro-intestinal tract.

May help to down-regulate inflammatory mediators in the gut.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Dosage Form

Powder, oral

Route of Administration


Visual Identification

Public Summary

Page 1 of

Produced at 26.11.2017 at 04:11:23 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Active Ingredients

Brassica oleracea var. italica

87.5 mg/g

Equivalent: Brassica oleracea var. italica (Fresh)

1.75 g/g

Choline bitartrate

62.5 mg/g

Curcuma longa

21.25 mg/g

Equivalent: Curcuma longa (Dry)

531.25 mg/g

cysteine hydrochloride

45.31 mg/g


187.5 mg/g


125 mg/g


50 mg/g


31.25 mg/g

Potassium sulfate

37.5 mg/g


125 mg/g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 26.11.2017 at 04:11:23 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

There are no safety alerts related to this product.


EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety